Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 12/20 | 0.61 |
| ▸ | GSR | P00390 | 1/20 | 0.61 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18497232 | 0.82 | TXNRD1 (0.56) | TXNRD1GSRPAX8MEN1RAB9A | |
| SCHEMBL28331489 | 0.81 | TXNRD1 (0.62) | TXNRD1GSRPAX8MEN1RAB9A | |
| SCHEMBL8595936 | 0.80 | PAX8 (0.50) | TXNRD1GSRPAX8MEN1RAB9A | |
| SCHEMBL8626897 | 0.80 | PAX8 (0.50) | TXNRD1GSRPAX8MEN1RAB9A | |
| SCHEMBL28332927 | 0.78 | TXNRD1 (0.60) | TXNRD1GSRPAX8MEN1RAB9A | |
| SCHEMBL8598745 | 0.78 | TXNRD1 (0.45) | TXNRD1GSRPAX8MEN1KMT2A | |
| SCHEMBL22280431 | 0.76 | TXNRD1 (1.00) | TXNRD1GSRVCAM1 | |
| SCHEMBL8596381 | 0.76 | TXNRD1 (0.49) | TXNRD1GSRMEN1KMT2AVCAM1 | |
| SCHEMBL9453001 | 0.75 | TXNRD1 (0.54) | TXNRD1GSRMEN1KMT2AALDH1A1 | |
| SCHEMBL2362856 | 0.75 | TXNRD1 (0.54) | TXNRD1GSRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899710-B2 | Pyridines and their use in the treatment of cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200087260-A1 | PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | The USA, as Represented by the Secretary, Department pf Health and Human Services (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3331858-A1 | PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | Arnér, Elias, Set Jenö (SE) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017027359-A1 | PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-02-16 | — | — | WO | disclosed |
| EP-0735025-B1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL CO (JP) | 1998-07-01 | — | — | EP | disclosed |
| US-5648496-A | AMINATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-07-15 | — | — | US | disclosed |
| EP-0735025-A1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899710-B2 | Pyridines and their use in the treatment of cancer | TP53, NDUFS3, NDUFS2 | TXNRD1 585/4885GSR 182/4885PAX8 2406/4885 |
| US-20200087260-A1 | PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | TP53, NDUFS3, NDUFS2 | TXNRD1 585/4885GSR 182/4885PAX8 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.